Gilead to acquire Cell Design Labs | December 18, 2017 Issue - Vol. 95 Issue 49 | Chemical & Engineering News
Volume 95 Issue 49 | p. 15 | Concentrates
Issue Date: December 18, 2017

Gilead to acquire Cell Design Labs

By Ryan Cross
Department: Business
Keywords: Biotechnology, immmunotherapy, Gilead, CAR T cell, CAR-T, Cell Design Labs

Gilead Sciences is expanding its cell therapy program by acquiring Emeryville, Calif.-based Cell Design Labs for up to $567 million. Cell Design Labs focuses on improving CAR T-cell immunotherapies, in which a person’s T cells are removed, edited, and reinjected to kill tumors. The firm’s technologies include an “on-off” switch for CAR T cells and novel receptors that could help T cells target cancerous cells while ignoring healthy ones. The buyout comes just two months after FDA approved a CAR T-cell therapy from Kite Pharma, which Gilead acquired in August for $11.9 billion.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment